Daclizumab clinical trials
Also written Zinbryta.
How each study uses Daclizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 10 Dec 1997 · Zenapax · BLA 103749 (FDA, Purple Book)
- European Union
- 26 Feb 1999 · Zenapax · EMEA/H/C/000198 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
54 studies that test it; most in 2002 (8)
| Year | Studies |
|---|---|
| 1996 | 1 |
| 1997 | 2 |
| 1999 | 7 |
| 2000 | 3 |
| 2001 | 5 |
| 2002 | 8 |
| 2003 | 6 |
| 2004 | 7 |
| 2005 | 5 |
| 2006 | 4 |
| 2007 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2013 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 40
National Eye Institute (NEI) (8) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · Hoffmann-La Roche (4) · Biogen (3) · University of Miami (2) · Johns Hopkins University (2) · National Institute of Neurological Disorders and Stroke (NINDS) (2) · Astellas Pharma Inc (2)
Often tested with
Tested in the same studies.
Mycophenolic Acid (7) · Thymoglobulin (5) · Sirolimus (5) · Tacrolimus (3) · Alemtuzumab (2) · Ganciclovir (2) · Infliximab (2) · Cyclosporine (2)
Related medicines
As reviewed, each with the page that says it.
- One of Immunosuppressive Agents source
Studies
Open first, then newest update. How each study uses Daclizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 54
- Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal TransplantationCompletedPhase 4University of MiamiNCT00685061Written as DaclizumabHow we know
- Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal TransplantationCompletedPhase 4University of MiamiNCT00681343Written as DaclizumabHow we know
- Phase I/II Thymus Transplantation With Immunosuppression #950CompletedPhase 1/2Sumitomo Pharma Switzerland GmbHNCT00579527Written as DaclizumabHow we know
- CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal TransplantationCompletedPhase 4EMagnussonNCT00246129Written as DaclizumabHow we know
- A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow FailureTerminatedPhase 2National Heart, Lung, and Blood Institute (NHLBI)NCT00001962Written as DaclizumabHow we know
- Prevention of Diabetes Progression Trial (PDPT)CompletedPhase 2Indiana University School of MedicineNCT00198146Written as ZenapaxHow we know
- New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical TrialCompletedPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT00100178Written as Daclizumab (DZB)How we know
- Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019TerminatedPhase 3BiogenNCT01797965Written as BIIB019 (Daclizumab)How we know
- Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic CancerCompletedPhase 2University of Maryland, BaltimoreNCT00006350Written as daclizumabHow we know
- Efficacy and Safety of Daclizumab in Participants With RRMS Switching From NatalizumabTerminatedPhase 3BiogenNCT02881567Written as DaclizumabHow we know
- Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple SclerosisCompletedPhase 2BiogenNCT01051349Written as BIIB019 (Daclizumab)How we know
- Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive CrossmatchCompletedPhase 3Johns Hopkins UniversityNCT00275509Written as DaclizumabHow we know
- The Use of Daclizumab and Anti-Thymocyte Globulin in Lung TransplantationCompletedPhase 2/3Johns Hopkins UniversityNCT00181142Written as ZenapaxHow we know
- Daclizumab to Treat HIV-Infected PatientsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00080431Written as DaclizumabHow we know
- ANTI-TAC THERAPY FOR UVEITISCompletedPhase 1National Eye Institute (NEI)NCT00001526Written as Daclizumab (Zenapax)How we know
- Daclizumab and Sirolimus to Treat UveitisCompletedPhase 1National Eye Institute (NEI)NCT00078689Written as DaclizumabHow we know
- Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple SclerosisCompletedPhase 2National Institute of Neurological Disorders and Stroke (NINDS)NCT00071838Written as DaclizumabHow we know
- Combination Daclizumab/Denileukin Diftitox to Treat UveitisCompletedPhase 2National Eye Institute (NEI)NCT00326508Written as DaclizumabHow we know
- Daclizumab to Treat Non-Infectious Sight-Threatening UveitisCompletedPhase 2National Eye Institute (NEI)NCT00070759Written as DaclizumabHow we know
- Islet Transplantation for Type 1 DiabetesCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00014911Written as DaclizumabHow we know
See all 54 studies that test Daclizumab →
Given beside what is tested · 5 — Daclizumab is usual care or a partner of the new treatment
- CCFZ533X2201 - PoC Study in de Novo Renal TransplantationCompletedPhase 1/2Novartis PharmaceuticalsNCT02217410Written as anti-IL2 InductionHow we know
- An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple SclerosisCompletedPhase 3BiogenNCT01462318Written as BIIB019 (Daclizumab)How we know
- Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant RecipientsCompletedPhase 3Hoffmann-La RocheNCT02686619Written as DaclizumabHow we know
- Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I DiabetesCompletedPhase 2AstraZenecaNCT00064714Written as daclizumab (immunosuppressive)How we know
- Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation After Kidney TransplantWithdrawnPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00790439Written as DaclizumabHow we know
As the comparator · 1 — what is tested is compared with Daclizumab
Codes
What other systems call Daclizumab · ClinicalTrials.gg INT006756
- MeSH (NLM) D000077561DaclizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) CUJ2MVI71YDACLIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 190353Confirmed FDA, Wikidata
- Wikidata Q412920daclizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1569DaclizumabOne source FDA
- DrugBank DB00111One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077561 | Daclizumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | CUJ2MVI71Y | DACLIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 190353 | — | Confirmed FDA, Wikidata |
| Wikidata | Q412920 | daclizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1569 | Daclizumab | One source FDA |
| DrugBank | DB00111 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.